No quarterly revenue total was found in Inhibitor Therapeutics, Inc.'s SEC filings.
Inhibitor Therapeutics, Inc. (INTI) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $515,758 in cash and investments and $21,566 in total debt.
Revenue
—
Net income
$-613,933
+7.0% vs year-ago quarter
Operating cash flow
$-775,220
-32.7% vs year-ago quarter
Free cash flow
—
EPS
$0.00
Dividend per share
None
Shares outstanding
173.79M
+0.7% vs year-ago quarter
Net cash
$494,192
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INTI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Tampa, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1042418
- Former names
- HedgePath Pharmaceuticals, Inc. (until Aug 12, 2019); COMMONWEALTH BIOTECHNOLOGIES INC (until May 20, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$618,597 | -$695,632 | -$1.3M | -$741,215 | -$695,773 |
| Net income | -$613,933 | -$686,425 | -$1.3M | -$712,184 | -$659,942 |
| Diluted EPS | $0.00 | $0.00 | -$0.01 | $0.00 | $0.00 |
| Operating cash flow | -$775,220 | -$1.1M | -$601,165 | -$761,245 | -$583,991 |
| Total assets | $637,190 | $1.4M | $2.5M | $3.1M | $3.9M |
| Total liabilities | $3.2M | $3.4M | $3.8M | $3.1M | $3.2M |
| Stockholders' equity | -$2.6M | -$2.0M | -$1.3M | $3,453 | $715,637 |
| Cash and investments | $515,758 | $1.3M | $2.4M | $3.0M | $3.7M |
| Total debt | $21,566 | $29,380 | $98,502 | $115,817 | $130,115 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 18, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 1, 2026 | Apr 1, 2026 |
| 8-K |
Current report
Other events
|
Apr 1, 2026 | Apr 1, 2026 |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
All 724 Inhibitor Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.